Business Wire

Kura Sushi to Reproduce Representative Dishes of 70 Countries and Regions Participating in the Osaka-Kansai Expo!

12.12.2024 02:00:00 CET | Business Wire | Press release

Share

70 Expo Special Menu Items UnveiledAntibacterial Sushi Covers with Expo-specific Designs Also Available

Kura Sushi Inc. (Headquarters: Sakai City, Osaka Prefecture), one of the world’s most popular conveyor-belt sushi chains, announced on December 12 that it will offer 70 new menu items at its restaurant that will open at the “Osaka-Kansai Expo,” which will open on April 13 next year in Yumeshima, Osaka, featuring dishes representing 70 countries and regions scheduled to participate in the Expo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211605079/en/

Antibacterial Sushi Covers with Expo-specific Designs (Photo: Business Wire)

The company is the only major revolving sushi chain in Japan to serve sushi on conveyor belts at all of its restaurants. Under the concept of “Revolving Belts Unite the World,” the company will open a restaurant at the Osaka-Kansai Expo with 338 seats, the most in the company’s history, and a revolving belt about 135 meters long, the longest in the company’s history.

With the intention to bring smiles to the faces of visitors from all over the world and provide them with an enjoyable dining experience, the “Hands・Hands Project,” a project that will offer a special 70 Expo menu representing each country and region scheduled to participate in the Expo, will be launched. The menu has been developed by the company’s product development team. The company’s product development team have been working on these menu items with a focus on reproducing the authentic flavors of the countries and regions. Twenty-four of the items have been recreated after being tasted and advised on by ambassadors and other people from these countries under the collaboration with each embassy.

In addition, the antibacterial sushi cover “Mr. Freshness,” which is being used for this special menu, has been specially designed with the connecting part appearing as red and blue hands shaking, the signature colors of the Expo. By serving the special menu side by side with the company’s popular sushi menu, sushi and dishes from different countries and regions flow hand in hand in front of the customers. Along with enjoying their meal, guests will be able to enjoy the experience as if they were visiting a pavilion that explores the culinary cultures of countries around the world.

To help building momentum for the Expo, special Expo menus will be offered ahead of time at about 550 restaurants nationwide, starting on February 7, 2025 (Friday). Each store will offer one item from a menu of 70 different items, as if each store were a “mini-pavilion” where visitors can enjoy the flavors of the respective country. As every neighborhood store will offer a different menu item from a different country or region, customers will be able to enjoy the menu at their local Kura Sushi restaurants, or they can enjoy all 70 items on the Expo special menu by visiting different Kura Sushi restaurants in Japan.

Kaitenzushi (Revolving Sushi Restaurant) is said to have spread throughout Japan after attracting attention at the Osaka Expo in 1970. Since then, Kaitenzushi has steadily expanded its market size while evolving in various ways over its 50-year history, and is now a leading business category in the evolution of the Japanese food service industry, with sales exceeding 800 billion yen. Going forward, the company will continue to leverage its strength, the revolving belt, to provide customers in Japan and overseas with the memorable enjoyment that only Kura Sushi can offer, thereby expanding the revolving sushi business model, a wonderful business model that originated in Japan, to the entire world.

Mr. Makoto Tanaka, Executive Vice President of Kura Sushi, held a press conference on the day of the event, and mentioned, “These days, the world is filled with a variety of social issues that are difficult to solve. Even under such circumstances, we hope that the conveyor-belt sushi restaurants, which are connected by a “conveyor belt that has no beginning and no end,” will unite people from all over the world who visit the Expo to have an enjoyable dining experience with a smile on their faces. We hope that visitors from all over the world, including Japanese customers, as well as tourists from all over the world, will enjoy the menu which we have created with the combined efforts of our Product Development Division to recreate the authentic flavors of the world.”

As of the end of November, Kura Sushi Inc. operates 547 restaurants in Japan, 70 in the United States, 59 in Taiwan, and 3 in Shanghai.

Check out our other products here. https://www.kurasushi.co.jp/2025expo/

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211605079/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye